Polycythemia Vera: Barriers to and Strategies for Optimal Management by Duminuco A, Harrington P, Harrison C, Curto-Garcia N

Get full text

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry) by Butt, N, Curto-Garcia, N, Ianotto, J, Harrison, C, Mead, A

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial by Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm by Salisbury, RA, Curto-Garcia, N, O'Sullivan, J, Chen, F, Polzella, P, Godfrey, AL, Russell, J, Knapper, S, Willan, J, Frewin, R, Joshi, S, Arami, S, Burns, S, Teh, CH, Wadelin, F, Dhanapal, J, Neelakantan, P, Milojkovic, D, Psaila, B, Szydlo, R, Francis, S, Cargo, C, Jain, M, McGregor, A, Wallis, L, Duncombe, A, Hussein, H, Dyer, P, Munro, L, Bond, L, McMullin, MF, Somervaille, TCP, Garg, M, Sekhar, M, Harrison, C, Mead, AJ, Innes, AJ